Hildred Capital Management Promotes Kevin Regan to Vice President

NEW YORK--(BUSINESS WIRE)--Hildred Capital Management, LLC (“Hildred”), a New York based private equity firm, today announced that Kevin Regan has been promoted to Vice President. Since joining the firm in 2020, Mr. Regan has been an instrumental member of the Investment Team, helping to identify, evaluate and execute high potential investments in healthcare and providing valuable operational and strategic support to the firm’s portfolio companies.

“Kevin’s diligent investment analysis and robust understanding of the healthcare industry has made him a significant contributor to our success in building a leading growth equity investment portfolio,” said Managing Partners David Solomon and Andrew Goldman. “We congratulate Kevin on his well-deserved promotion and are excited to see what he accomplishes in his new, expanded role.”

Mr. Regan joined Hildred from Centre Lane Partners in September 2020 as a Senior Associate. At Centre Lane, he was responsible for investment across various sectors including healthcare, business services, consumer products, industrials, software, media and technology and worked closely with portfolio company board members and management teams. Prior to Centre Lane, Mr. Regan worked as an Investment Banking Analyst in J.P. Morgan’s Leveraged Finance Group where he focused on originating leveraged loans, high yield bonds and bridge facilities in the technology, media and telecommunications sectors.

Mr. Regan graduated magna cum laude with a B.A. in Financial Economics with Honors from the University of Rochester, where he received the Barry Rapoport Prize for general excellence in the field of economics and the William Morse Hastings Essay Prize for the best thesis on a topic of economic research.

About Hildred Capital Management:

Hildred is a New York-based private equity investment firm that pursues growth equity investments in middle market healthcare companies with leading products, technologies, and services. Hildred invests in companies with revenues of up to $100 million and creates value from pursuing organic growth strategies, driving effective resource allocation, implementing operational improvements, generating business development, and supporting best-in-class management teams. Areas with attractive fundamentals where Hildred may invest include the following healthcare subsectors: healthcare services, consumer products, information technology, medical devices, life science tools and diagnostics, healthcare related development and manufacturing, and pharmaceuticals, as well as related businesses that impact these healthcare subsectors. For more information, please visit www.hildredcapital.com.


Hugh Burns/Pamela Greene